AbbVie Commands 30% Forward P/E Premium Over Pharma Peers
BMY•AbbVie trades at a forward P/E of roughly 18x, about 30% above the pharma peer group average of 14x, reflecting investor confidence in its immunology and oncology franchises. This premium valuation underscores robust Skyrizi and Rinvoq sales but may constrain future stock upside relative to lower‐valued rivals.
1. Valuation Comparison
AbbVie currently trades at a forward P/E of roughly 18x, approximately 30% above the 14x average of its major pharmaceutical peers, marking it as the highest‐valued stock in its peer group. Investors are paying a premium multiple that could limit further upside if sector valuations compress.
2. Pipeline and Growth Drivers
The valuation gap reflects robust revenue growth from immunology leaders Skyrizi and Rinvoq, each delivering double-digit sales increases over the past year. Anticipated oncology trial readouts and expanding global launches are cited as key drivers sustaining AbbVie’s premium multiple.
